Squamous cell carcinoma of the esophagus | UniteRare Disease Library

as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior…

as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy

View Details →FDA Label ↗Copay Card ↗Patient Assistance ↗

Tevimbra

tislelizumab-jsgr· BeOne Medicines USA, Inc.

in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)

View Details →FDA Label ↗

Clinical Trials

20 recruitingView all trials with filters →

Phase 34 trials

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Phase 3

Actively Recruiting

· Sites: Tianjin, Tianjin Municipality · Age: 18–75 yrs

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Phase 3

Active

PI: Clinical Trial (Hoffmann-La Roche) · Sites: Fort Myers, Florida; Wichita, Kansas +163 more · Age: 18–99 yrs

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 3

Actively Recruiting

· Sites: Zhengzhou, Henan; Zhengzhou, Henan · Age: 18–70 yrs

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3

Actively Recruiting

· Sites: Fullerton, California; Detroit, Michigan +86 more · Age: 18–99 yrs

Other16 trials

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Actively Recruiting

PI: Koichi Takiguchi, PhD (City of Hope Medical Center) · Sites: Chūō, Yamanashi · Age: 20–99 yrs

a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study

Active

· Sites: Hangzhou, Zhejiang · Age: 18–90 yrs

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Actively Recruiting

PI: Xiao L Ge, PHD (The First Affiliated Hospital with Nanjing Medical) · Sites: Nanjing, Jiangsu · Age: 18–99 yrs

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

Actively Recruiting

· Sites: Hefei · Age: 18–85 yrs

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Actively Recruiting

· Sites: Wuhan, Hubei · Age: 18–80 yrs

Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)

Actively Recruiting

PI: Hong Yang, M.D.;Ph.D. (Sun Yat-Sen University Cancer Center) · Sites: Guangzhou, Guangdong

The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）

Active

· Sites: Shijiazhuang, Hebei · Age: 18–99 yrs

Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer

Actively Recruiting

· Sites: Shanghai, Shanghai Municipality · Age: 18–99 yrs

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

Active

PI: Department of Etiology and Carcinogenesis (Cancer Hospital Chinese Academy of Medical Scienc) · Sites: Beijing, Beijing Municipality · Age: 18–99 yrs

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Actively Recruiting

PI: Di Ge, MD (Fudan University) · Sites: Shanghai, Shanghai Municipality · Age: 18–75 yrs

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

Actively Recruiting

PI: Lei Zheng (Nanfang Hospital, Southern Medical University) · Sites: Guangzhou · Age: 18–75 yrs

Tumor Regression Grade As Predictor of Adjuvant Therapy

Actively Recruiting

PI: Bin Zheng (Key Laboratory of Cardio-Thoracic Surgery, Fujian ) · Sites: Fuzhou, Fujian · Age: 18–99 yrs

Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma

Actively Recruiting

PI: Koichi Takiguchi, PhD (City of Hope Medical Center) · Sites: Nagoya, Aichi-ken; Chūō, Yamanashi · Age: 20–99 yrs

Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

Actively Recruiting

PI: Yangkai Li, MD, PhD (Tongji Hospital) · Sites: Wuhan, Hubei · Age: 18–99 yrs

Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab

Actively Recruiting

· Sites: Hefei · Age: 18–99 yrs

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Actively Recruiting

· Sites: London, Greater London; Cottingham, Hull +11 more · Age: 18–90 yrs

Specialists

Showing 25 of 93View all specialists →

CP

chang j h, post-doctor

Specialist

Carcinoma of esophagus

PI on 1 active trial

Active trials Directions Travel grants

KM

Kuaile Zhao, MD

Specialist

Carcinoma of esophagus, salivary gland type

PI on 3 active trials

Active trials Directions Travel grants

RH

Razvan Hainarosie

Specialist